CYTK
Cytokinetics Inc
65.60$
+0.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 21,833.9% | 5,082.3% | 9,768.9% | 31,966.7% | 18,274.7% | 553.1% | 6,323.1% | 3.4% | 138.4% | 16.1% | 12.4% | 8.6% | 15.0% | |
| -21,733.9% | -4,982.3% | -9,668.9% | -31,866.7% | -18,174.7% | -453.1% | -6,223.1% | 96.6% | -38.4% | 83.9% | 87.6% | 91.4% | 85.0% | |
| 21,833.9% | 5,082.3% | 9,768.9% | 31,966.7% | 18,274.7% | 553.1% | 6,323.1% | 168.6% | 5,125.7% | 571.9% | 493.5% | 306.5% | 555.4% | |
| 10,611.4% | 2,638.4% | 5,449.1% | 20,411.2% | 12,235.9% | 368.3% | 3,633.2% | 98.4% | 3,587.7% | 516.6% | 542.0% | 327.1% | 522.1% | |
| 10,611.4% | 2,638.4% | 5,449.1% | 20,411.2% | 12,235.9% | 368.3% | 3,633.2% | 263.6% | 8,575.0% | 1,088.5% | 1,036.3% | 642.6% | 1,078.0% | |
| -32,345.2% | -7,620.7% | -15,118.0% | -52,277.9% | -30,410.6% | -821.4% | -9,856.3% | -167.0% | -8,613.4% | -1,004.6% | -948.7% | -551.1% | -993.0% | |
| 3,702.6% | 1,020.6% | 2,074.4% | 9,758.6% | 4,816.0% | 133.5% | 1,453.2% | 36.3% | 1,359.6% | 170.9% | 172.2% | 109.1% | 175.9% | |
| -34,238.6% | -8,187.6% | -16,244.7% | -57,557.4% | -34,674.9% | -886.3% | -10,220.1% | -201.2% | -15,815.0% | -1,030.9% | -1,064.5% | -622.8% | -1,259.9% | |
| 1,819.7% | 110.5% | 274.0% | – | – | – | – | – | – | – | – | – | – | |
| -34,238.6% | -8,187.6% | -16,244.7% | -57,557.4% | -34,674.9% | -886.3% | -10,220.1% | -201.2% | -15,815.0% | -1,030.9% | -1,064.5% | -622.8% | -1,259.9% | |
| -30,045.5% | -6,788.1% | -13,891.1% | -46,832.5% | -29,338.2% | -738.7% | -8,621.3% | -161.5% | -14,317.0% | -1,015.8% | -874.8% | -600.8% | -1,153.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.